CLR1404 enters malignant cells through special areas of the cell membrane termed 'lipid rafts'. The marked selectivity of CLR1404 for malignant cells versus non-malignant cells is due to the fact that malignant cells have far more lipid rafts. Once inserted into the cell membrane lipid rafts of malignant cells, CLR1404 is then transported into the cells through binding to the cell protein AKT as well as through a normal cellular process termed pinocytosis which is used to take in nutrients. Both processes lead to the accumulation of CLR1404 in the malignant cells.
News Update
Cellectar Clinical Trial News Cellectar Completes Enrollment In Phase I Clinical Trial of Lead Drug Candidate 131I-CLR1404 For The Treatment of Solid Malignancies
Cellectar, Inc. Begins GMP Production Radiopharmaceutical production facility to support clinical development for lead drug candidate and other molecules.
